Recardio is a clinical-stage life science company developing regenerative therapies for cardiovascular diseases, led by founder, president and CEO Dr. Roman Schenk. Its lead therapeutic candidate, Dutogliptin, is a DPP-4 inhibitor that has demonstrated significant effects in activating SDF-1, a protein critical for cardiac regeneration. The company has initiated a Phase 1/2 clinical program and is positioning the platform as a regenerative medication for acute myocardial infarction and chronic heart failure. Recardio intends to use newly raised funds to advance a Phase 2 clinical trial for Dutogliptin. The company recently relocated its headquarters from Klagenfurt, Austria to San Francisco while retaining Klagenfurt as its European hub. Financially, Recardio secured $3M in a Series A financing from existing shareholders and several new undisclosed investors.

Total raised

$3M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2015